Mark R. Middleton
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers.
Journal: BJC reports
Published: February 08, 2025
Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.
Journal: Journal for immunotherapy of cancer
Published: March 31, 2024
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Journal: The Lancet. Oncology
Published: June 23, 2023
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Journal: Journal for immunotherapy of cancer
Published: May 12, 2023
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Journal: Cancer cell
Published: August 02, 2022
VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 10, 2021
Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis.
Journal: Gastroenterology
Published: November 26, 2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 02, 2020
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Journal: British journal of cancer
Published: March 17, 2020
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Journal: British journal of cancer
Published: December 19, 2019
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 22, 2019
Last Updated: 09/26/2026